News25/Ratings0
News · 26 weeks68-37%
2025-10-262026-04-19
Mix4090d
- Insider15(38%)
- Other14(35%)
- SEC Filings9(23%)
- Offering2(5%)
Latest news
25 items- SECSEC Form D filed by Polyrizon Ltd.D - Polyrizon Ltd. (0001893645) (Filer)
- SECSEC Form F-1 filed by Polyrizon Ltd.F-1 - Polyrizon Ltd. (0001893645) (Filer)
- SECSEC Form 6-K filed by Polyrizon Ltd.6-K - Polyrizon Ltd. (0001893645) (Filer)
- SECSEC Form 424B5 filed by Polyrizon Ltd.424B5 - Polyrizon Ltd. (0001893645) (Filer)
- PRPolyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private PlacementsRAANANA, ISRAEL, April 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the closing of its previously announced registered direct offering and concurrent private placement with a single institutional investor. The Company issued Ordinary Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also issued to the same investor pre-funded and investor warrants. Aggregate gross proceeds to the Company from both transactions were approximately $3.5 million. The transactions closed on April 8, 2026. The transacti
- PRPolyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private PlacementRAANANA, ISRAEL, April 07, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has entered into definitive agreements with a single institutional investor for the purchase and sale of its Ordinary Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investor pre-funded and investor warrants. Aggregate gross proceeds to the Company from both transactions are expected to be approximately $3.5 million. The transactions consisted of the sale of 388,888 Units (or Pre-Funded Uni
- INSIDERSEC Form 4 filed by Carmel Liron4 - Polyrizon Ltd. (0001893645) (Issuer)
- INSIDERSEC Form 4 filed by Izraeli Tomer4 - Polyrizon Ltd. (0001893645) (Issuer)
- INSIDERSEC Form 4 filed by Adler Oz4 - Polyrizon Ltd. (0001893645) (Issuer)
- INSIDERSEC Form 4 filed by Turgeman Tidhar4 - Polyrizon Ltd. (0001893645) (Issuer)
- INSIDERSEC Form 4 filed by Izraeli Tomer4 - Polyrizon Ltd. (0001893645) (Issuer)
- INSIDERSEC Form 4 filed by Carmel Liron4 - Polyrizon Ltd. (0001893645) (Issuer)
- SECAmendment: SEC Form 20-F/A filed by Polyrizon Ltd.20-F/A - Polyrizon Ltd. (0001893645) (Filer)
- PRPolyrizon Provides 2025 and Recent HighlightsRaanana, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, provided 2025 and recent a business update. "Polyrizon has delivered significant progress across its innovative nasal programs, including key regulatory advancements with the FDA, preparation for potential human clinical trials, and valuable medical collaborations, all powered by a strong cash position and a debt-free balance sheet," said Tomer Izraeli, chief executive officer of Polyrizon. Key Highlights of Polyrizon's Achievements in 2025 and Recent Highlights: As of December 31, 2025, t
- PRPolyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025Raanana, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the "SEC"). The report is available on the SEC's website, at www.sec.gov and Polyrizon's Investor Relations website, at https://investor.polyrizon-biotech.com/. Shareholders can obtain copies of Polyrizon's Annual Report on Form 20-F, free of charge, by making a request within a reasonable period of time to Polyrizon's Investor Relat
- SECSEC Form 20-F filed by Polyrizon Ltd.20-F - Polyrizon Ltd. (0001893645) (Filer)
- PRPolyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility ApplicationsThe Company signed a non-binding MOU with shareholders of Colugo. Colugo's customer include the Israel Defense Forces, national first responders organizations and commercial companies Raanana, Israel, March 24, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the signing of a non-binding Memorandum of Understanding ("MOU") with shareholders of Colugo Systems Ltd. ("Colugo"), an innovative Israeli developer of advanced electric Vertical Take-Off and Landing (eVTOL) drone systems, for the acquisition of up to 20% stake in Colugo. Established in 2016,
- INSIDERSEC Form 3 filed by Polyrizon Ltd.3 - Polyrizon Ltd. (0001893645) (Issuer)
- INSIDERSEC Form 3 filed by Polyrizon Ltd.3 - Polyrizon Ltd. (0001893645) (Issuer)
- INSIDERSEC Form 3 filed by Polyrizon Ltd.3 - Polyrizon Ltd. (0001893645) (Issuer)
- INSIDERSEC Form 3 filed by Polyrizon Ltd.3 - Polyrizon Ltd. (0001893645) (Issuer)
- INSIDERSEC Form 3 filed by new insider Vinokur Yehonatan Zalman3 - Polyrizon Ltd. (0001893645) (Issuer)
- INSIDERSEC Form 3 filed by Polyrizon Ltd.3 - Polyrizon Ltd. (0001893645) (Issuer)
- INSIDERSEC Form 3 filed by new insider Izraeli Tomer3 - Polyrizon Ltd. (0001893645) (Issuer)
- INSIDERSEC Form 3 filed by new insider Adler Oz3 - Polyrizon Ltd. (0001893645) (Issuer)